Compare Oscar Health Inc (OSCR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Oscar Health Inc trades at $33.25 (market cap $10.22B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.5× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OSCR | VRTX | |
|---|---|---|
Market Cap | $10.22B | $127.55B |
Volume | 4,123,394 | 1,487,944 |
Sector | Health | Health |
52-Week High | $33.81 | $557.96 |
52-Week Low | $10.85 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | $6.57B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $32.91, up 1.76% today, with a bullish technical outlook from moving averages and mixed oscillators. The stock shows strong revenue growth, with 2026 revenue projected at $15.3B, and profitability turning positive with a net income margin of 3.59%. Recent news highlights market share gains in the ACA sector and raised 2026 guidance, though Q3 2026 EPS is yet to be reported.
The outlook is positive with analyst consensus at Buy and a $34 price target, but risks include rising medical costs and execution challenges. Upside potential exists from scalable growth and margin expansion, yet volatility near resistance levels and competitive pressures warrant caution for investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
